BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: Transparency Market Research has published a new report titled, “Dementia Associated with Alzheimer’s Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The demand within the global market for ophthalmology surgical devices has been rising on account of the rising incidence of eye diseases and disorders, finds Transparency Market Research.

Orexo AB, announces it has successfully initiated the first explorative human clinical study for OX640, an adrenaline rescue medication with nasal delivery.

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Antoine Gravelle as General Counsel, effective July 1st, 2022.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Tuesday, August 2, 2022 at 8:30 a.m. ET.

Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced participation at the William Blair Biotech Focus Conference.

OrthoPediatrics Corp. announced today that it has completed the previously announced acquisition of Pega Medical for $33 million.

89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the closing of its upsized underwritten public offering of 18,675,466 shares of its common stock and accompanying warrants to purchase up to 9,337,733 shares of common stock at a combined public offering price of $3.55.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today the full cash pre-payment of its unsecured convertible promissory note dated November 4, 2020, as amended November 16, 2021 (the “Note”).

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2022 after the close of trading on Tuesday, August 2.